Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Inks Blue Cross and Blue Shield Contract

NEW YORK (GenomeWeb News) – Transgenomic said today that it has expanded a national contractual agreement with the Blue Cross and Blue Shield Association.

The Omaha, Neb.-based molecular diagnostics and pharmacogenomics services firm said in a filing with the US Securities and Exchange Commission that the new agreement has a term of five years. Under the contract, Blue Plans affiliates have access to "competitive pricing" for Transgenomic's tests and services.

The firm didn't provide any additional details of the contract.

Transgenomic offers genetic analysis kits for a variety of mutations, including BRAF, KRAS, and NRAS. The kits feature the company's Ice-Cold-PCR technology.

in Friday afternoon trade on the OTC Market shares of Transgenomic were up 14 percent at $.48.